Unlike other ALK inhibitors for which the main side effects were hepatotoxicity and gastrointestinal upset, common adverse effects of lorlatinib included hypercholesterolemia (72%), hypertriglyceridemia (39%), peripheral neuropathy (39%), and peripheral edema (39%) [236]. The gene discussed is ALK; the disease is peripheral neuropathy.